Artiva Biotherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARTV Nasdaq 2836 www.artivabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today - Jun 8th, 2026 4:30 am
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - May 28th, 2026 6:00 am
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases - May 19th, 2026 2:05 pm
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development - May 19th, 2026 6:00 am
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - May 8th, 2026 4:52 am
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights - May 8th, 2026 4:31 am
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026 - May 8th, 2026 4:30 am
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans? - Apr 17th, 2026 12:15 pm
Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham - Apr 15th, 2026 4:02 pm
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - Apr 8th, 2026 6:00 am
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - Mar 10th, 2026 2:05 pm
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update - Mar 4th, 2026 1:13 pm
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - Feb 25th, 2026 6:00 am
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant - Feb 24th, 2026 6:00 am
AtaiBeckley names Michael Faerm as finance chief - Feb 19th, 2026 6:21 am
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors - Feb 19th, 2026 6:00 am
Undervalued Penny Stocks To Consider In January 2026 - Jan 26th, 2026 11:05 am
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL - Jan 21st, 2026 6:00 am
Artiva Biotherapeutics (ARTV): Evaluating Valuation After CEO’s Latest Insider Share Sale - Dec 19th, 2025 4:14 pm
Rocket Pharmaceuticals Leads Our Trio Of Penny Stock Contenders - Dec 17th, 2025 5:04 am